Presenter: Matthew, Cooper, Washington, DC, USA
Authors: Matthew Cooper
Despite a clear demonstration of the benefits of solid-organ pancreas transplantation for patients with diabetes mellitus, volumes continue to decrease throughout the US. Improvements in quality of life and the ability to abrogate the complications of dysregulated glucose control has now allowed the procedure to be offered to many with Type 2 DM. Indications and patient selection, however, are critical both to individual outcomes and to further advance national support of pancreas transplantation for all. This webinar will share both published data and personal experience on program resources and patient demographics that remain important in the evaluation and transplantation of patients with Type 2 DM.
Matthew Cooper is a Professor of Surgery at Georgetown School of Medicine and the Director of Kidney and Pancreas Transplantation at the Medstar Georgetown Transplant Institute (MGTI), UNOS surgical director for the Pediatric Kidney Transplant program at Children’s National Medical Center and the Medical Director for Quality and Safety for Medstar Georgetown University Hospital.
After receiving his medical degree from the Georgetown University School of Medicine in 1994, Dr Cooper completed his general surgery training at the Medical College of Wisconsin followed by a fellowship in multi-organ abdominal transplantation in 2002 at the Johns Hopkins Hospital in Baltimore, MD. He joined the transplant faculty at the Johns Hopkins Hospital upon completion of his training and was appointed Surgical Director of Kidney Transplantation and Clinical Research in 2003. Dr. Cooper joined the University of Maryland in 2005 directing the kidney transplant and clinical research program until 2012 following which he assumed his current role in Washington, DC.
Dr. Cooper trained with the pioneers of the laparoscopic donor nephrectomy procedure, regularly performs living donor surgeries and seeks new opportunities for living donation through innovation and by removing the disincentives for those considering donation while promoting the safety and long-term care of live organ donors. His clinical interests included kidney and pancreas transplantation; particularly the use of marginal organs and is currently organizing a collaborative to decrease kidney allograft discards. Dr. Cooper is involved in several ongoing clinical research projects primarily with an interest in immunosuppression minimization and amelioration of delayed graft function in kidney allografts following ischemic reperfusion injury. He has authored over 100 peer-reviewed manuscripts and 6 book chapters.Dr. Cooper is involved in transplantation activities both locally in the District and on a national basis. He is a member of the National and DC Board of Directors for the NKF and a member of the NKF’s National Transplant Task Force, Public Policy Committee and Living Donor Executive Committee. He recently served as the chairman of the United Network of Organ Sharing’s Living Donor Committee and currently acts as the Associate Councillor for UNOS’ Region 2 and vice-chair for the Membership and Professional Committee. He is a current board member for the American Foundation for Donation and Transplantation and the local OPO – Washington Regional Transplant Community. Dr. Cooper is on the Executive Committee for the ATC Planning Committee and is a member of the AST Living Donor Community of Practice.
By viewing the material on this site you understand and accept that: